New drug BDC-4182 targets stomach cancer by waking up the immune system
NCT ID NCT06921837
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will enroll 122 participants to check safety and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BDC-4182, an immune-stimulating antibody conjugate that targets claudin 18.2 on cancer cells and activates the immune system
What this could lead to
If successful, this could lead to a new treatment option for advanced gastric and gastroesophageal cancers that have stopped responding to standard therapies.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AUS Site 1
RECRUITINGBirtinya, Queensland, Australia
Contact
-
AUS Site 2
RECRUITINGDarlinghurst, New South Wales, Australia
Contact
-
AUS Site 3
RECRUITINGHeidelberg, Victoria, Australia
Contact
-
AUS Site 4
RECRUITINGClayton, Victoria, Australia
Contact
-
AUS Site 5
RECRUITINGWestmead, New South Wales, Australia
Contact
-
SK Site 2001
RECRUITINGSeoul, South Korea
Contact
-
SK Site 2002
RECRUITINGSeoul, South Korea
Contact
-
SK Site 2003
RECRUITINGSeongnam-si, South Korea
Contact
-
SK Site 2004
RECRUITINGSeoul, South Korea
Contact
-
SK Site 2005
RECRUITINGSeoul, South Korea
Contact
-
TWN Site 9001
RECRUITINGTaichung, Taiwan
Contact
-
TWN Site 9002
RECRUITINGTaoyuan, Taiwan
Contact
-
TWN Site 9003
RECRUITINGTaipei, Taiwan
Contact
-
TWN Site 9004
RECRUITINGKaohsiung City, Taiwan
Contact
-
TWN Site 9005
RECRUITINGKaohsiung City, Taiwan
Contact
-
TWN Site 9006
RECRUITINGTaipei, Taiwan
Contact